Skip to content
OpenCapital
Get started

OS Therapies OSTX Q4 2025 Annual earnings

Reported March 31, 2026

Diluted EPS-$0.37Miss by $0.23
EPS estimate-$0.14

Next report

Aug 17, 2026 (in a month)
Revenue estimate$511.0K
EPS estimate-$0.25

Financials

Q4 2025

Income statement

See full
Operating income-$12.0M-304%
Net income-$13.5M-350%
EPS (diluted)-$0.41+35.9%

Balance sheet

See full
Cash & equivalents$269.8K-95.1%
Total equity-$6.1M-86.6%
Total assets$6.8M+23.5%

Cash flow

See full
Operating cash flow-$3.7M-57.1%
Free cash flow-$3.7M—

Versus estimates

Diluted EPS

Q1 2026-$0.27Miss by $0.10
Q4 2025-$0.37Miss by $0.23
Q3 2025-$0.21Miss by $0.05Q2 2025-$0.19Miss by $0.04Q1 2025-$0.18Miss by $0.07Q4 2024-$0.24Miss by $0.10

Ask the moment OS Therapies reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did OS Therapies report Q4 2025 earnings?
OS Therapies (OSTX) reported Q4 2025 earnings on March 31, 2026.
What were OS Therapies's Q4 2025 revenue and EPS?
OS Therapies reported diluted EPS of $-0.36 for Q4 2025.
Did OS Therapies beat estimates in Q4 2025?
EPS missed the consensus estimate of $-0.14 by $0.23.
How did OS Therapies's Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, diluted EPS declined 52.1% from $-0.24.
Where can I find OS Therapies's Q4 2025 SEC filings?
You can read the 8-K earnings release (0001213900-26-037476) and the 10-K periodic report (0001213900-26-036629) directly on SEC EDGAR. The filing index links above go to sec.gov.